100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
2484719-08-4Abiraterone Related Compound 5
● Under Development
| Catalogue No.: | VL830011 |
|---|---|
| CAS No.: | 2484719-08-4 |
| Mol. Formula: | C24H31F3O6S |
| Mol. Weight: | 504.56 g/mol |
Additional information on CAS 2484719-08-4
Parent drug
AbirateroneIUPAC Name
(3S, 8R, 9S, 10R, 13S, 14S)-10, 13-dimethyl-17-(2-(((trifluoromethyl)sulfonyl)oxy)acetyl)-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetatePharmacopoeial Synonyms
N/AOther Synonyms
Abiraterone Pregnenolone-16-ene Acetate 21-Triflate;P regna-5,16-dien-20-one, 3-(acetyloxy)-21-[[(trifluoromethyl)sulfonyl]oxy]-, (3β)Smiles
CC(O[C@H]1CC[C@]2(C)[C@@]3([H])CC[C@]4(C)C(C(COS(=O)(C(F)(F)F)=O)=O)=CC[C@@]4([H])[C@]3([H])CC=C2C1)=OInChI
InChI=1S/C24H31F3O6S/c1-14(28)33-16-8-10-22(2)15(12-16)4-5-17-18-6-7-20(23(18,3)11-9-19(17)22)21(29)13-32-34(30,31)24(25,26)27/h4,7,16-19H,5-6,8-13H2,1-3H3/t16-,17-,18-,19-,22-,23-/m0/s1Description
Abiraterone Related Compound 5Â is poorly absorbed and is susceptible to hydrolysis by esterases and is an orally active inhibitor of the steroidal enzyme CYP17A1 that is used in the treatment of prostate cancer.References
Thakur, Abhimanyu, et al. “Abiraterone Acetate in the Treatment of Prostate Cancer.†Biomedicine & Pharmacotherapy, vol. 101, May 2018, pp. 211–218, 10.1016/j.biopha.2018.02.067.Request a Quote
"*" indicates required fields
Other products related to Abiraterone impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
